Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2000
07/20/2000CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
07/20/2000CA2360366A1 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
07/20/2000CA2360358A1 Compositions having improved stability
07/20/2000CA2360356A1 .beta.-phenylalanine derivatives as integrin antagonists
07/20/2000CA2360232A1 Telomerase inhibitors
07/20/2000CA2360227A1 Pharmaceutical mixture comprising a combination of a profen and other active compounds
07/20/2000CA2360060A1 Steroid derived antibiotics
07/20/2000CA2359990A1 Novel aralkyl amines of spirofuropyridines useful in therapy
07/20/2000CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000CA2359952A1 Triazole compounds with dopamine-d3-receptor affinity
07/20/2000CA2359942A1 Triazole compounds with dopamine-d3-receptor affinity
07/20/2000CA2359678A1 Use of s-triazines for treating apicomplexan parasitic infections
07/20/2000CA2359569A1 Reductive alkylation of secondary amines with hydrosilane
07/20/2000CA2359562A1 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
07/20/2000CA2359557A1 Process and products of purification of anhydrosugar alcohols
07/20/2000CA2359479A1 Novel complex-forming proteins
07/20/2000CA2359478A1 Administration of an anti-endotoxin drug by intravenous infusion
07/20/2000CA2359474A1 Particles for oral delivery of peptides and proteins
07/20/2000CA2359449A1 Phenanthridine-n-oxides with pde-iv inhibiting activity
07/20/2000CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity
07/20/2000CA2359404A1 Phenanthridine-n-oxides with pde-iv inhibiting activity
07/20/2000CA2359390A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
07/20/2000CA2359381A1 Medicament forms having controlled release and containing active substances which easily dissolve in water
07/20/2000CA2359365A1 Anti-cd3 immunotoxins and therapeutic uses therefor
07/20/2000CA2359349A1 A method for introducing substances into cells, and use of said method
07/20/2000CA2359335A1 Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
07/20/2000CA2359273A1 Pharmaceutical formulations containing an opioid and an .alpha.-agonist
07/20/2000CA2359253A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
07/20/2000CA2359244A1 .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
07/20/2000CA2359110A1 Combination of hepatitis b vaccine with antiviral agents
07/20/2000CA2358748A1 Reagents and methods useful for detecting diseases of the breast
07/20/2000CA2358662A1 Therapeutic compositions for metabolic bone disorders or bone metastases
07/20/2000CA2358638A1 Composition and methods for administration of water-insoluble paclitaxel derivatives
07/20/2000CA2357726A1 Chorionic gonadotropin dna vaccines and methods
07/20/2000CA2356990A1 Composition and method for improving function of embryonic kidney transplants
07/20/2000CA2356944A1 Compositions having improved stability
07/20/2000CA2356934A1 Serine protease inhibitors
07/20/2000CA2356850A1 Dry skin remedies
07/20/2000CA2356776A1 Transcutaneous photodynamic treatment of targeted cells
07/20/2000CA2356532A1 Noninvasive vascular therapy
07/20/2000CA2356440A1 New dialysis method
07/20/2000CA2356290A1 Benzenic sulphonamide derivatives and their uses
07/20/2000CA2355792A1 New amidinobenzylamine derivatives and their use as thrombin inhibitors
07/20/2000CA2355374A1 1-heterocycle substituted diarylamines
07/20/2000CA2353088A1 Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
07/20/2000CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors
07/20/2000CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
07/20/2000CA2349180A1 Anthranilic acid derivatives
07/20/2000CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
07/20/2000CA2328092A1 Method of isolating mucilaginous polysaccharides and uses thereof
07/20/2000CA2325359A1 Novel lrsg protein and nucleic acid molecules and uses therefor
07/20/2000CA2323711A1 Composition for treating obesity and aesthetic treatment method
07/20/2000CA2296224A1 Use of imidazo(1,5-a)pyrido(3,2-e)pyrazinones
07/19/2000EP1020519A1 Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors
07/19/2000EP1020474A1 Oligosaccharide derivatives and process for producing the same
07/19/2000EP1020471A1 Process for producing UCN-01
07/19/2000EP1020470A2 Galanthamine derivatives, a process for their preparation and their use as medicaments
07/19/2000EP1020469A2 Galanthamine derivatives, a process for their preparation and their use as medicaments
07/19/2000EP1020465A1 Stereoisomeric indole compounds, process for the preparation of the same, and use thereof
07/19/2000EP1020464A1 Paroxetine methansulfonate
07/19/2000EP1020463A1 Paroxetine methanesulfonate
07/19/2000EP1020461A2 Use of alkaline salts of the (-)-enantiomer of omeprazole
07/19/2000EP1020460A2 The sodium salt of the (-)-enantiomer of omeprazole
07/19/2000EP1020459A1 Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
07/19/2000EP1020458A1 Optically active 1,4-benzodioxine-2-carboxylic acid derivatives and process for producing the same
07/19/2000EP1020452A1 Benzimidazole derivatives
07/19/2000EP1020439A1 Cetp activity inhibitors
07/19/2000EP1020426A1 Amine derivatives and process for producing the same
07/19/2000EP1020193A1 Oral preparation
07/19/2000EP1020192A2 Composition against cellulitis
07/19/2000EP1020191A1 Medicaments for hypolipidemic and hypoglycemic conditions
07/19/2000EP1020190A2 Treatment of BPH with cGMP elevators
07/19/2000EP1020189A1 Prophylactic or therapeutic agent for amnesia
07/19/2000EP1020188A1 New use of taxoid derivatives
07/19/2000EP1020187A1 Pharmaceutical compositions containing hydroximic acid derivatives
07/19/2000EP1020186A2 Sustained release tramadol preparations with a storage stable release profile and process for their manufacture
07/19/2000EP1020185A2 Opioid analgesics with controlled release
07/19/2000EP1020184A1 Sustained release tablets containing bupropion hydrochloride
07/19/2000EP1020183A2 Analgesic composition with controlled release
07/19/2000EP1020181A1 Process for producing pellets with a pharmaceutical agent content of up to 90% w/w
07/19/2000EP1020180A2 Biocompatible, injectable aqueous solution for use in ultrasound energy assisted surgery
07/19/2000EP1019728A1 Method of activating a novel ligand regulatory pathway
07/19/2000EP1019726A1 Prevention of sudden infant death
07/19/2000EP1019714A2 Diagnosis of williams syndrome and williams syndrome cognitive profile by analysis of the presence or absence of a lim-kinase gene
07/19/2000EP1019533A1 Silanol enzyme inhibitors
07/19/2000EP1019530A1 A method of treating cancer
07/19/2000EP1019529A1 A method of treating cancer
07/19/2000EP1019506A1 101 human secreted proteins
07/19/2000EP1019500A2 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
07/19/2000EP1019499A2 Methods and compositions for inducing tumor-specific cytotoxicity
07/19/2000EP1019497A1 Hammerhead ribozymes with extended cleavage rule
07/19/2000EP1019435A1 Amplification of response from expressed recombinant protein
07/19/2000EP1019434A2 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis
07/19/2000EP1019431A1 Novel rnase p
07/19/2000EP1019429A1 Antisense and antigene therapeutics with improved binding properties and methods for their use
07/19/2000EP1019428A2 Inverted chimeric and hybrid oligonucleotides
07/19/2000EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators
07/19/2000EP1019426A1 Novel a 1? adenosine receptor agonists and antagonists
07/19/2000EP1019425A1 Modified benzimidazole nucleosides as antiviral agents